Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
Posted 10 April 2012 | By Alexander Gaffney, RAC
The US Food and Drug Administration (FDA) issued an updated safety warning 10 April about birth control products containing drospirenone-a synthetic version of the hormone progesterone-saying the hormone may be associated with a higher risk for blood clots than other progesterone-based pills.
Some studies highlighted by FDA showed a three-fold increase in the risk of developing a blood clot, though FDA admitted "it is unclear whether the increased risk seen for blood clots in some of the epidemiologic studies is actually due to drospirenone-containing birth control pills."
"The studies reviewed did not provide consistent estimates of the comparative risk of blood clots between birth control pills that contain drospirenone and those that do not," said FDA in a statement. "The studies also did not account for important patient characteristics (known and unknown) that may influence prescribing and that likely affect the risk of blood clots."
FDA noted some birth control products, including Beyaz and Yasmin will require revised drug labels.
The products were recently the subject of a Wall Street Journal investigation, which found that the advisory committee advising FDA on the product's safety had among its members at least three members with existing financial ties to Bayer, the drug's manufacturer.
The Journal's report unleashed a torrent of criticism from groups like the Project on Government Oversight, which asked FDA Commissioner Margaret Hamburg to investigate.
FDA soon fired back at mounting criticism, saying that critics exhibited a "lack of understanding about our selection and evaluation process."
The issue has mostly laid dormant since late January, but FDA's notice of increased risks associated with the drospirenone products is likely to bring the issue back into focus.
FDA - FDA Drug Safety Communication: Updated information about the risk of blood clots in women taking birth control pills containing drospirenone
Regulatory Focus - WSJ: Panel Assessing Bayer Birth Control Pills Had Ties to Company
Regulatory Focus - POGO Lambastes FDA Over Conflict of Interest Report
Regulatory Focus - FDA Responds to Conflict of Interest Uproar
Tags: Beyaz, Drospirenone, Yasmin, Yaz, Birth Control, Blood Clots, Bayer, Latest News, Hamburg
Regulatory Focus newsletters
All the biggest regulatory news and happenings.